scholarly journals Can volumetric modulated arc radiation therapy reduce organ at risk dose in stage 4 sinonasal tumors in dogs treated with boost irradiation?

PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0259112
Author(s):  
Valeria Meier ◽  
Felicitas Czichon ◽  
Linda Walsh ◽  
Carla Rohrer Bley

Intensity modulated radiation therapy (IMRT) introduced marked changes to cancer treatment in animals by reducing dose to organs at risk (OAR). As the next technological step, volumetric modulated arc therapy (VMAT) has advantages (increased degrees-of-freedom, faster delivery) compared to fixed-field IMRT. Our objective was to investigate a possible advantage of VMAT over IMRT in terms of lower OAR doses in advanced-disease sinonasal tumors in dogs treated with simultaneously-integrated boost radiotherapy. A retrospective, analytical, observational study design was applied using 10 pre-existing computed tomography datasets on dogs with stage 4 sinonasal tumors. Each dataset was planned with both, 5-field IMRT and 2 arc VMAT with 10x4.83 Gy to the gross tumor volume and 10x4.2 Gy to the planning target volume. Adequate target dose coverage and normal tissue complication probability of brain ≤5% was required. Dose constraints aspired to were D60 <15 Gy for eyes, D2 <35.4 Gy for corneae, and Dmean <20 Gy for lacrimal glands. OAR dose was statistically significantly higher in IMRT plans than in VMAT plans. Median eye D60% was 18.5 Gy (interquartile range (IQR) 17.5) versus 16.1 Gy (IQR 7.4) (p = 0.007), median lacrimal gland dose 21.8 Gy (IQR 20.5) versus 18.6 Gy (IQR 7.0) (p = 0.013), and median cornea D2% 45.5 Gy (IQR 6.8) versus 39.9 Gy (IQR 10.0) (p<0.005) for IMRT versus VMAT plans, respectively. Constraints were met in 21/40 eyes, 7/40 corneae, and 24/40 lacrimal glands. Median delivery time was significantly longer for IMRT plans than for VMAT plans (p<0.01). Based on these results, VMAT plans were found to be superior in sparing doses to eyes, lacrimal glands, corneae. However, not all ocular OAR constraints could be met while ensuring adequate dose coverage and restricting brain toxicity risk for both planning techniques.

2010 ◽  
Vol 9 (2) ◽  
pp. 77-85 ◽  
Author(s):  
Courtney Buckey ◽  
Gregory Swanson ◽  
Sotirios Stathakis ◽  
Nikos Papanikolaou

AbstractBackground and Purpose: Intensity-modulated radiation therapy (IMRT) is considered by many to be the standard of care in the delivery of external-beam radiotherapy treatments to the prostate. The purpose of this study is to assess the validity of the purported benefits of IMRT.Materials and Methods: Treatment plans were produced for 10 patients using both 3D conformal radiation therapy (3D-CRT) and IMRT, utilising the dose constraints recommended by the Radiation Therapy Oncology Group (RTOG) 0415 protocol. Three IMRT modalities used in this study were linear accelerator based IMRT, helical tomotherapy, and serial tomotherapy. The prescription to the target, 76 Gy, was the same for all plans.Results: In general the 3D-CRT plans satisfied the RTOG criteria for planning target volume (PTV) coverage, and met or bettered the dose criteria for the organs at risk. PTV coverage was more homogeneous for the IMRT plans than the 3D-CRT plans but not significantly improved.Conclusions: Technically, because the IMRT plans required greater effort for the optimisation, longer treatment times and higher monitor units, the use of IMRT for the fulfilment of the protocol’s dosimetric goals was not justified using these constraints.


2019 ◽  
Vol 2019 ◽  
pp. 1-16
Author(s):  
Yanqiu Zhang ◽  
A’meng Han ◽  
Zhanzhao Fu ◽  
Shufeng Xu ◽  
Zijian Zhang

Currently, studies about PORT in stage IIIA-N2 NSCLC patients in recent years have mostly adopted the conformal radiation therapy (CRT) technique, while other modern techniques such as intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT, hereinafter referred to as ARC), helical tomotherapy (HT), and so forth are also developing quickly. In this paper, we intended to compare the dosimetric characteristics of CRT, IMRT, ARC, CRT+IMRT, and CRT+ARC of PORT in stage IIIA-N2 NSCLC patients. Ten patients with stage IIIA-N2 completely resected NSCLC, whom were treated by PORT in the radiotherapy department of our hospital from January 1, 2017, to January 1, 2018, were randomly selected in this study. For each patient, the CRT plan, IMRT plan, ARC plan, CRT+IMRT plan, and CRT+ARC plan were designed separately on the same set of CT images. The isodose distribution and dose-volume histogram (DVH) of the five plans were compared to determine the dosimetric parameters of the targets, OAR (organs at risk), and the normal tissue (defined as body subtracted to PTV (planning target volume), B-P). No plan had absolute dosimetry advantages than any other plans. In clinical practice, the plans could be chosen according to their dosimetry characteristics.


Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3744
Author(s):  
Pierre Loap ◽  
Ludovic De Marzi ◽  
Alfredo Mirandola ◽  
Remi Dendale ◽  
Alberto Iannalfi ◽  
...  

Consolidative radiation therapy for early-stage Hodgkin lymphoma (HL) improves progression-free survival. Unfortunately, first-generation techniques, relying on large irradiation fields, were associated with an increased risk of secondary cancers, and of cardiac and lung toxicity. Fortunately, the use of smaller target volumes combined with technological advances in treatment techniques currently allows efficient organs-at-risk sparing without altering tumoral control. Recently, proton therapy has been evaluated for mediastinal HL treatment due to its potential to significantly reduce the dose to organs-at-risk, such as cardiac substructures. This is expected to limit late radiation-induced toxicity and possibly, second-neoplasm risk, compared with last-generation intensity-modulated radiation therapy. However, the democratization of this new technique faces multiple issues. Determination of which patient may benefit the most from proton therapy is subject to intense debate. The development of new effective systemic chemotherapy and organizational, societal, and political considerations might represent impediments to the larger-scale implementation of HL proton therapy. Based on the current literature, this critical review aims to discuss current challenges and controversies that may impede the larger-scale implementation of mediastinal HL proton therapy.


2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 586-586
Author(s):  
H. Mok ◽  
C. H. Crane ◽  
T. Briere ◽  
S. Beddar ◽  
M. E. Delclos ◽  
...  

586 Background: In the treatment of rectal cancer, a strong dose-volume relationship exists between the amount of small bowel receiving low- to intermediate-doses of radiation and the rates of acute, severe gastrointestinal toxicity. Highly conformal treatment approaches, such as intensity-modulated radiation therapy (IMRT), may reduce dose to adjacent organs-at-risk (OAR). We performed a dosimetric evaluation of IMRT compared to 3-dimensional conformal radiation therapy (3DCRT) in standard, preoperative treatment for rectal cancer. Methods: Using RTOG consensus contouring atlas, treatment volumes were generated for ten patients treated preoperatively, with IMRT plans compared to 3DCRT plans derived from classic anatomic landmarks, as well as modified 3DCRT plans treating the RTOG consensus volume. The patients were all T3, were node-negative (N=1) or node–positive (N=9), and were planned to a total dose of 45-Gy. Bowel displacement was achieved using a carbon-fiber bellyboard apparatus with prone positioning. Results: IMRT plans had superior PTV coverage, dose homogeneity, and conformality in treatment of the gross disease and at-risk nodal volume, in comparison to 3DCRT. Additionally, in comparison to the modified 3DCRT plans, IMRT achieved a concomitant reduction in doses to the bowel, bladder, pelvic bones, and femoral heads, with an improvement in absolute volumes of small bowel receiving dose levels known to induce clinically-relevant acute toxicity. In the six patients with the highest volume of small bowel (range: 209-537-cc), the volume of bowel receiving 15-Gy was reduced from a median of 224-cc in the modified 3DCRT plans to 185-cc with IMRT. Also, the IMRT volumes were typically larger than that covered by classic 3DCRT fields, without incurring penalty with respect to adjacent OAR. Conclusions: For rectal carcinoma, IMRT, compared to 3DCRT, yielded plans with superior target coverage, homogeneity, and conformality, while lowering dose to adjacent OAR. This is despite treating larger volumes, raising the possibility of a clinically-relevant improvement in the therapeutic ratio through the use of IMRT with a belly-board apparatus. No significant financial relationships to disclose.


2021 ◽  
Vol 18 (2) ◽  
Author(s):  
Magdalena Charmacińska ◽  
Sara Styś ◽  
Olga Bąk ◽  
Weronika Kijeska ◽  
Agnieszka Skrobała

Nowotwór piersi jest to nowotwór złośliwy powstający z komórek gruczołu piersiowego, który rozwija się miejscowo w piersi oraz daje przerzuty do węzłów chłonnych i narządów wewnętrznych (płuc, wątroby, kości i mózgu). Ponad 23% zachorowań na nowotwory kobiet w Polsce, jak i na świecie stanowią nowotwory piersi. Na przestrzeni ostatnich lat techniki napromieniania nowotworów piersi ulegają ciągłemu rozwojowi. Celem pracy było poglądowe przedstawienie technik radioterapeutycznych stosowanych w napromienianiu nowotworów piersi, od dwuwymiarowej 2D techniki statycznej poprzez techniki dynamiczne (IMRT technika z modulacją intensywnością dawki (ang. intensity modulated radiation therapy), VMAT technika obrotowa z modulacją intensywności dawki (ang. volumetric modulated arc therapy), aż do techniki DIBH techniki napromieniania na głębokim wstrzymanym wdechu (ang. deep inspiration breath hold). W pracy skupiono się na przedstawieniu realizacji omawianych technik i opisie jak dana technika wpływa na rozkład dawki w planowanej objętości do napromieniania PTV (ang. Planning Target Volume) oraz na dawki w narządach krytycznych w radioterapii nowotworów piersi.


Sign in / Sign up

Export Citation Format

Share Document